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INTRODUCTION
Drug repurposing or repositioning, the use of drugs 
for indications other than what they were initially intended, 
has been offered as a strategy for drug development in 
oncology programs. This approach has special potential 
for childhood cancers and other rare or orphan diseases, 
where the expected return on new drug development has 
been a disincentive to pharmaceuticals [1, 2]. Historically, 
oncology agents are approved for pediatric cancers only 
after efficacy is demonstrated in adult tumors. Hence, 
repurposing drugs that particularly have known safety 
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ABSTRACT
Drug repurposing approaches have the potential advantage of facilitating rapid and 
cost-effective development of new therapies. Particularly, the repurposing of drugs with 
known safety profiles in children could bypass or streamline toxicity studies. We employed 
a phenotypic screening paradigm on a panel of well-characterized cell lines derived from 
pediatric solid tumors against a collection of ~3,800 compounds spanning approved 
drugs and investigational agents. Specifically, we employed titration-based screening 
where compounds were tested at multiple concentrations for their effect on cell viability. 
Molecular and cellular target enrichment analysis indicated that numerous agents across 
different therapeutic categories and modes of action had an antiproliferative effect, 
notably antiparasitic/protozoal drugs with non-classic antineoplastic activity. Focusing 
on active compounds with dosing and safety information in children according to the 
Children’s Pharmacy Collaborative database, we identified compounds with therapeutic 
potential through further validation using 3D tumor spheroid models. Moreover, we 
show that antiparasitic agents induce cell death via apoptosis induction. This study 
demonstrates that our screening platform enables the identification of chemical agents 
with cytotoxic activity in pediatric cancer cell lines of which many have known safety/
toxicity profiles in children. These agents constitute attractive candidates for efficacy 
studies in pre-clinical models of pediatric solid tumors.
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profiles in children and adolescents could streamline or 
directly bypass toxicity studies, making these drugs more 
appealing to providers and patients [3, 4].  
Drug repurposing in childhood cancers may occur in 
several ways [5]. One serendipitous way is the observation 
of unintended antineoplastic benefits of drugs that have 
been prescribed for different indications. This has been 
the path to repurposing several drugs which now have 
childhood cancer indications [3, 4, 6, 7].  Another way 
includes more systematic hypothesis-driven approaches 
based on mining existing drug and structural databases 
[8–13].  A third approach to repurposing, which exploits 
the polypharmacology of drugs to discover new drug 
indications, is the use of phenotypic screening [14–17]. 
This approach interrogates drug candidates in pediatric 
cancer models in an unbiased fashion and has the 
advantage of providing information on large numbers of 
drugs in relatively short periods of time. Additionally, 
identifying approved drugs with previously unrecognized 
anticancer properties has the potential to reveal new 
mechanisms and biological processes involved in 
carcinogenesis or drug resistance.
In this study, we performed phenotypic screening on 
19 well-characterized cell lines derived from solid tumors 
seen in children and adolescents against a collection of 
3,886 unique compounds spanning approved drugs and 
investigational agents [18–21]. Specifically, we employed 
a titration-based screening paradigm (quantitative high-
throughput screening or qHTS), where all compounds 
were tested at multiple concentrations for their effect 
on cell viability [22]. Thus, concentration-response 
curves (CRCs) were derived directly from the primary 
screen, and both potency and efficacy values were used 
to identify compounds with robust bioactivity profiles. 
By combining this approach with available information 
associated with drug annotations, we found numerous 
agents across different therapeutic categories and modes 
of action that had an antiproliferative effect. Among these 
we found antiparasitic/protozoal and other drugs with 
non-classic antineoplastic mode of action. We focused 
validation studies mainly on compounds that are present 
in our Children’s Pharmacy Collaborative (CPC) database, 
a comprehensive list of drugs with dosing and safety 
profiles in children (0–18 years old) [4]. Specifically, we 
implemented a high-throughput multiparametric assay 
utilizing three-dimensional (3D) cell cultures as in vitro 
models of pediatric cancers to further validate compound 
activity. Moreover, we show that selected antiparasitic 
agents induce cytotoxicity by activating apoptosis-
mediated cell death.
By combining phenotypic screening data and CPC 
information, our platform enables the identification of 
chemical agents with cytotoxic activity in pediatric cancer 
cell lines as well as known safety/toxicity profiles in 
children. These agents constitute attractive candidates for 
efficacy studies in clinical trials of pediatric solid tumors.
RESULTS
To identify new therapeutic options for pediatric 
cancer, we screened the NIH Chemical Genomics Center 
(NCGC) Pharmaceutical Collection (NPC)[21] and 
Mechanism Interrogation Plate (MIPE) [18–20] small 
molecule collections of approved and investigational drugs 
using a 1,536-well format qHTS assay against a panel 
of pediatric cancer cell lines. The panel consisted of 19 
well-characterized cell lines derived from childhood solid 
tumors, namely Ewing’s sarcoma (EWS), central nervous 
system (CNS) tumors (medulloblastoma, glioblastoma, and 
atypical teratoid rhabdoid tumor [ATRT]), neuroblastoma 
(NB), osteosarcoma (OS), and rhabdomyosarcoma 
(RMS) (Table 1 and Supplementary Table 1). Of note, 
all cell lines actively proliferate in the time course of the 
assay (Supplementary Figure 1). The assay measured 
metabolically active cells after 48 hours of compound 
treatment as a proxy for cell viability. For each of the 19 
cell lines tested, we derived concentration-response curves 
(CRCs) for 4,728 compounds (comprising 3,886 unique 
compounds), and we used both potency and efficacy 
values to identify compounds with robust bioactivity 
profiles (definition of activity and cutoffs are described in 
Materials and Methods and assay performance is described 
in Supplementary Table 2). Briefly, compounds exhibiting 
high-quality dose-response curves, IC50 of ≤ 10 µM, 
and maximal response ≥ 65% were considered as active. 
A total of 1,120 compounds were active against one or 
more cell lines (Supplementary Figure 2A). Unsupervised 
clustering of pharmacological responses of active 
compounds indicated that not all cell lines clustered based 
on their tumor type of origin (Supplementary Figure 2B). 
This is not surprising given that each tumor type is only 
represented by a small number of cell lines; also, the 
artificially grouped “CNS tumor” category contains 
representative cell lines from three different tumor types. 
Interestingly, rhabdomyosarcoma lines are among the 
cell lines with fewer number of hits (most resistant) and 
EWS lines among the ones with greater number of hits 
(most sensitive) (Supplementary Figure 2C). A total of 62 
compounds, referred herein to as pan-actives, were active 
across 17 or more cell lines (Supplementary Figure 2D). 
Target-based analysis of the pharmacological responses 
indicated an overrepresentation of DNA topoisomerase, 
histone deacetylase (HDAC), Interleukin-2-inducible T 
cell kinase (ITK), Janus kinase 2 (Jak2), phosphoinositide 
3-kinase (PI3K), and proteasome inhibitors among pan-
actives (Supplementary Figure 2E). Interestingly, 36 of 
these pan-actives had minimal activity (inactive or did 
not pass potency and/or efficacy cutoffs) against human 
wild-type fibroblasts (Hh-Wt-fibroblasts) indicating their 
activity is not the result of non-specific cytotoxic effects. 
To confirm activity, 736 compounds were selected for 
retesting in secondary follow-up screens against the panel 
of cell lines.  Criteria for selection included one or more of 
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the following: availability in our repository; activity against 
the majority of cell lines in the primary screen (pan-active 
compounds); selective activity against multiple cell lines 
within a tumor type (selective compounds); and finally, 
strong activity (IC50 of <100 nM) against at least one cell 
line (potent compounds). To support our drug repurposing 
effort the retesting set included compounds covering a 
diverse range of mechanisms of action and with and without 
known antineoplastic activity. Using the same activity 
cutoffs as in the primary screen, of the 736 compounds 
retested, 502 (68.2%) showed activity against one or more 
cell lines in any tumor category (Figure 1A, Supplementary 
Table 3 and Supplementary Table 4). In agreement with 
the primary screen, cell lines from Ewing’s sarcomas were 
among those with higher number of hits (most sensitive), 
with approximately 350 active compounds (Figure 1B). In 
the retest, 45 compounds showed a relatively broad range of 
in vitro activity with cytotoxicity against multiple cell lines 
(pan-actives, Figure 1C). In concordance with the primary 
screen, pan-active compounds were enriched for DNA 
topoisomerase and HDAC inhibitors, and the vast majority 
either have been or are being investigated for antineoplastic 
indications (Figure 1D). Dose-response curves of select 
pan-active compounds are shown in Supplementary Figure 
3. Among these pan-actives, 27 compounds exert minimal 
activity against human fibroblasts cells (Supplementary 
Figure 3B).
Activity outcomes of retested compounds 
rendered by tumor types identified 26 tumor-specific 
compounds that showed activity against two or more 
cell lines from the EWS tumor category (Figure 2A and 
Supplementary Figure 4). While the majority of these 
compounds have known antineoplastic effects, other have 
diverse indications such as antivirals, antiprotozoal and 
antiarrhythmic (Figure 2B and Supplementary Table 5). 
A recent study by Pessetto et al. reported an in vitro drug 
screening of an FDA-approved drug library against a 
set of EWS cell lines, of which A673 was also screened 
in our panel [17]. The authors identified 45 drugs with 
activity against EWS lines and minimal activity against 
non-tumorigenic control lines. Remarkably, among the 45 
hits, 28 compounds were also included in our re-test set 
and 23 of these were active against EWS lines, including 
auranofin. However, none of the 23 active agents were 
specific for EWS lines since they also showed activity 
against other tumor lines included in our study.
Table 1: Cell lines used in the study 
Cell Line
Tumor Type Name Source
EWS 
A673 UNC
TC32 UNC
SK-N-MC UNC
CNS: Glioblastoma SJ-GBM2 PPT
CNS: Medulloblastoma Daoy UNC
 CNS: ATRT
BT-12 UNC
BT-37 UNC
NB 
LAN-5 UNC
NB1643 PPT
NB-EBc1 PPT
SK-N-SH UNC
OS 
MG 63 (6-TG R) UNC
OHS-50 UNC
Saos-2 UNC
U-2 OS UNC
RMS
RD UNC
Rh18 UNC
Rh30 PPT
Rh41 PPT
Control Hh-Wt-fibroblasts CI
EWS: Ewing’s sarcoma; CNS: Central Nervous System; ATRT: atypical teratoid rhabdoid tumor; NB: Neuroblastoma; OS: 
Osteosarcoma; MG 63 (6-TG R): 6-Thioguanine Resistant MG 63 cell line; RMS: Rhabdomyosarcoma. Sources: UNC: 
University of North Carolina; PPT: Pediatric Preclinical Testing Program; CI: Coriell Institute.
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Potency analysis among active compounds in 
the follow-up screen identified 90 compounds with 
potencies lower than 100 nM against at least one cell line 
(Supplementary Table 6). DNA topoisomerase, proteasome, 
mechanistic target of rapamycin (mTOR) and tubulin 
polymerization inhibitors were the most represented 
mechanisms with potent activity (Supplementary Figure 5). 
Although the majority (~58%) of active agents 
from the follow-up screen have oncology indications or 
are being studied for antineoplastic effects, ~42% have a 
primary indication other than cancer. Among the latter, we 
found compounds used as antiparasitics and antiprotozoals 
(Figure 3 and Supplementary Table 7).  Antiparasitic/
protozoal agents have been hypothesized by others to 
play anticancer roles [23–26]. In fact, several drugs in 
clinical use against these diseases, such as mebendazole, 
are currently in clinical trials for childhood cancers [27]. 
Similarly, antiinflammatory agents, in particular non-
steroidal (NSAIDs) and glucocorticoids, have also been 
linked to antineoplastic effects [28–30].  
We have previously reported a comprehensive and 
growing resource, the Children’s Pharmacy Collaborative 
(CPC) database, a listing of all drugs for which there are 
some dosing and safety information for children (0–18 
years old) [4]. Of the 3,886 unique compounds included 
in the NPC and MIPE collections, 875 are also part of 
our CPC database. A total of 111 compounds that are 
active in our screen against one or more cell lines (and 
have minimal activity against Hh-Wt fibroblasts) are 
part of the CPC (Supplementary Table 8). Overall, the 
majority of active compounds approved for pediatric 
uses belong to the antineoplastic category (Figure 4). 
Among these agents we find drugs used in childhood 
cancers such as dactinomycin, vincristine, topotecan, 
etc. However, several drugs which are known to be 
effective against childhood cancers did not demonstrate 
the expected cytotoxicity in our screening. Drugs such 
as cyclophosphamide, platinating agents (carboplatin 
and cisplatin), and temozolomide, which either require 
activation in vivo (cyclophosphamide), are inactive as 
Oncotarget4762www.impactjournals.com/oncotarget
DMSO solutions (platinating agents), or have a short half-
life in vitro, did not demonstrate activity in this system as 
might have been expected. Nine other anticancer agents, 
including sorafenib, vorinostat, and romidepsin did not 
meet criteria for activity in this assay.
In addition to antineoplastics, other compounds 
with cytotoxic activity against multiple pediatric cancer 
lines that are also present in the CPC include antiviral, 
antiparasitic/protozoal agents, as well as compounds with 
antiinflammatory and immunosuppressant indications 
as discussed above. Our screens indicated that cardiac 
glycosides such as digitoxin, digoxin, and oubain and 
β-adrenoreceptor agonists such as isoprotenerol and 
dobutamine, also display cytotoxic effects in cancer cell 
lines. These agents, traditionally used for the treatment of 
heart diseases, have also shown cytotoxic effects in cancer 
cell lines as well as in vivo xenograft models in numerous 
studies [31–38]. Among these agents (Supplementary 
Figure 6), digitoxin and dobutamine are included in the 
CPC and may merit follow up studies.
It is well established that three-dimensional (3D) 
cell cultures provide structural and cellular morphological 
Figure 1: Follow-up studies validate compound activity. (A) Hierarchical clustering of compound activity rendered by tumor 
type. Compound activity is represented as AUC (Area Under the Curve) values. AUC values are colored red, with darker color indicating 
compounds that are more potent and efficacious. (B) Distribution of active agents by tumor type. (C) Hierarchical clustering of pan-active 
compounds (active in 17 cell lines or more) based on potency. LogIC50 values are colored in blue, with darker color indicating more 
potent compounds. Inactive compounds that have no IC50 values determined are shown in grey. (D) Target-based analysis of pan-active 
compounds in follow-up screen. For each compound, the average IC50 across all cell lines in shown.
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complexity that can lead to different responses to 
therapeutic compounds compared to traditional monolayer 
cultures. Multicellular tumor spheroids is one of the most 
well characterized 3D culture systems, and combined with 
the ability to perform medium-throughput  screening of 3D 
spheroids, it has become a cell-line platform to evaluate 
the therapeutic efficacy of anticancer agents [39–42]. 
Therefore, we sought to further validate compound 
activity in 3D multicellular tumor spheroids of pediatric 
cancer cell lines developed as in vitro solid tumor models. 
Specifically, we developed a multiparametric qHTS assay 
in 384-well format to monitor the effect of compounds on 
spheroid viability (Supplementary Figure 7). Briefly, cells 
were cultured in 384-well ultra-low attachment (ULA) 
plates for 48 hours to allow the formation of spheroids, 
which were subsequently treated with selected compounds 
in dose response. After 72 hour incubation, spheroid 
viability was first quantified via propidium iodide (PI, 
which stains dead cells) and Hoechst 3342 (which stains 
all cells) imaging and subsequently with CellTiter-Glo 
(3D). Importantly, the diameter of untreated spheroids 
increases during the time course of the assay, suggesting 
active cell proliferation (Supplementary Figure 8). We 
selected a representative cell line of each tumor type to 
grow as spheroids under ultra-low attachment (ULA) 
conditions. Specifically, we chose TC32 from Ewing’s 
sarcoma, MG 63 (6-TG R) from osteosarcoma, RD from 
rhabdomyosarcoma, SK-N-SH from neuroblastoma, 
and Daoy and SJ-GBM2 from CNS tumors of the 
medulloblastoma and glioblastoma types, respectively. 
Neither cell line of the ATRT type formed spheroids 
under these conditions (data not shown). To identify 
new therapeutic options for pediatric solid cancers, we 
tested 60 compounds that were active in our phenotypic 
screen, 41 of which have safety/dosing profiles in 
children. The 60 compounds have mainly antineoplastic, 
anti-inflammatory, antiviral and antiparasitic/protozoal 
indications (Supplementary Table 9). Compound activity 
was determined based on the CellTiter-Glo parameter as 
before because of overall better assay statistics compared 
to imaging parameters (Supplementary Table 2). 
Nevertheless, compound potency determined using both 
Figure 2: Compounds with specific activity against EWS cancer cell lines. (A) Clustering of retested compounds rendered by 
tumor type identifies EWS-specific agents. Hierarchical clustering of compound activity based on AUC (Area Under the Curve) values 
rendered by tumor type. AUC values are colored red, with darker color indicating compounds that are more potent and efficacious. 
(B) Dose response curves of EWS-specific antineoplastic agents. Exemplified are the purine nucleoside analogs (or antimetabolite) 
Nelarabine, and Pentostatin and the alkylating agent ThioTEPA.
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Figure 3: Indication of active compounds identified in the follow-up screen. (A) Fraction of compounds that are active against 
one or more cell line. The category labeled as “Other” contains indications represented by 1 compound. (B) Dose response of active 
antiparasitic/protozoal agents. X-axis represents Log[M].
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CellTiter-Glo and imaging parameter is overall well 
correlated, except for MG 63 (6-TG R) and Daoy lines 
(Supplementary Figure 9). 
A comparison of compound potency in 2D vs. 3D 
cultures indicated low to moderate correlation depending 
on the cell line, with several compounds displaying 
differential activity between formats. For instance, 
some compounds (particularly the antiviral acyclovir 
and the PARP inhibitor veliparib) showed cytotoxicity 
in 3D cultures despite being inactive (no cytotoxicity 
at maximum concentration tested or potency >10 µM) 
in the corresponding monolayer culture. Conversely, 
other compounds that showed cytotoxic activity in 2D 
monolayers were inactive (no cytotoxicity at maximum 
concentration tested or potency >10 µM cutoff) in 3D 
spheroid cultures. Among these, 7 compounds including 
the antiinflammatory agents ibuprofen, mometasone, 
and deflazacort did not show activity in any of the 3D 
cultures tested (Supplementary Figure 10). The remaining 
compounds reduced the viability of spheroids of at least 
one cell line, with 17 compounds displaying pan-activity 
across all 6 spheroid types. Pan-actives include not 
surprisingly antineoplatics agents such as adriamycin, 
bortezomib, and quisinostat but also the cardiotonic 
glycoside digitoxin and the antiparasitics emetine 
and niclosamide. In fact, all antiparasitic/protozoal 
agents tested show cell viability effects in 3D cultures 
(Figure 5). To determine if the cytotoxic effect elicited 
by antiparasitic/protozoal was due to apoptosis-mediated 
cell death, we quantified caspase-3/7 activation in TC32 
spheroids using the CellEvent Caspase-3/7 green detection 
imaging reagent (Figure 6A). We found that all tested 
compounds induced strong caspase-3/7 activation with 
the exception of pyrimethamine (Figure 6B), which agrees 
with the lack of activity in the viability assay (Figure 5). 
Niclosamide and artesunate showed moderate caspase 
activity. In the case of artesunate, its effect was also in 
agreement with the viability assay; however, niclosamide 
was clearly active in the viability assay, indicating that it 
might elicit cell death via additional mechanisms. Most 
of these antiparasitic agents are included in the CPC and 
hence constitute good candidates for follow up in vivo 
studies in children. 
DISCUSSION
In contrast to hypothesis-driven testing of small 
numbers of compounds against childhood cancers, such as 
that performed by the NCI’s PPTP [43], phenotypic HTS 
can provide information on large numbers of drugs and cell 
types in short periods of time. Moreover, many repurposed 
drugs act by apparently different mechanisms for their 
different indications, arguing for broad, mechanism-agnostic 
drug screening. In this study, we report the quantitative 
profiling of 19 pediatric cancer cell lines against a collection 
of ~3,800 approved and investigational drugs. We identified 
and validated over ~500 compounds with cytotoxic activity 
against one or more cell lines. Strengthening our approach, 
the majority of active compounds found in the screen have 
known antineoplastic indications or are being investigated 
for oncology purposes. However, some active hits have 
not generally been recognized as having activity against 
pediatric and/or adult cancer cell lines. Among the latter, 
we find compounds used as antiparasitics, antiprotozoals, 
antiinflammatories as well as agents for the treatment 
of heart diseases. We further validated the activity of 53 
compounds in 3D tumor models of pediatric cancers using 
a multiparametric qHTS assay. Specifically, we found that 
antiparasitics reduce TC32 cell viability via induction of 
apoptosis.
Importantly for the intended pediatric repurposing, 
over 100 active compounds identified in our screen (~50% 
of which were also validated in 3D spheroid assays) 
are also included in our CPC database. Some of these 
drugs, such as the immunosupressants primecolimus, 
mycophenolic acid and related mycophenolate mofetil 
Figure 4: Active compounds with dosing/safety information in children. Fraction of compounds that are active against one 
or more cell line and are part of the CPC. A total of 111 were grouped by indication. The category labeled as “Other” contains indications 
represented by 1 compound.
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Figure 5: Antiparasitic/protozoal agents are active in 3D cultures. (A) Representative images of spheroids treated with indicated 
agents (at 30 µM, except Niclosamide which was tested at 15 µM), for 72 hours and stained with Hoechst 3342 (blue) and PI (red). (B) Dose 
response curves of indicated agents treated as above but obtained by CellTiter-Glo (3D). X-axis indicates compound concentration in Log[M].
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have been used in children and/or adolescents for very 
different primary indications and if preclinical efficacy is 
verified by other assays (such as in vivo xenograft models), 
they should represent attractive candidates for phase II 
clinical trials. Antiparasitic such as mebendazole and 
difluoromethylornithine (DFMO) are currently in clinical 
trials for pediatric brain tumors and neuroblastomas. Our 
findings further indicate that antiparasitics could have 
therapeutic potential for a broad range of tumor types.
Our study has several limitations. Most importantly, 
although our extensive quantitative profiling of nearly 
four thousand drugs generated over half a million data 
Figure 6: Antiparasitic/protozoal agents induce apoptosis in TC32 spheroids. (A) Representative images of TC32 spheroids 
treated with indicated agents for 24 hours and stained with Caspase3/7-Alexa488 (green). Compounds were tested in dose response ranging 
from 30 µM to 0.5 nM, except Niclosamide, which was tested in the range of 15 µM to 0.25 nM. (B) Dose response curves of indicated 
agents. Data are represented as % Caspase-3/7 activation compared to staurosporine control.
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points, we studied a relatively small number of cell lines 
of several tumor types, which particularly limits the 
identification of tumor-specific agents. In addition, paired 
control cell lines for each tumor type might better reflect 
broad vs. cancer-specific compound activity. For the 
primary and secondary screens, the assay readout is only 
a proxy for cell viability and orthogonal readouts might 
strengthen these findings, as seen in our 3D spheroid 
validation assay. Finally, efficacy in other biologically 
relevant models of childhood cancer, such as xenograft 
studies, should be tested to corroborate our findings.
We conclude that phenotypic qHTS is a valuable 
approach to identify new compounds and classes of 
drugs which merit additional attention for the treatment 
of pediatric solid tumors. In concert with informatics 
approaches, qHTS is useful for prioritizing drugs that 
already have safety profiles in children further facilitating 
drug development for pediatric solid tumors. The dataset 
generated here, along with the CPC, is fully available to 
the scientific community, and we hope that it will serve as 
valuable resource to accelerate drug repurposing. 
MATERIALS AND METHODS
Cell lines and culture conditions
As shown in Table 1 and Supplementary Table 
1, cell lines were obtained from the National Cancer 
Institute’s Pediatric Preclinical Testing Program (NCI, 
PPTP) [44], maintained at Nationwide Children’s 
Hospital, Columbus, OH and from laboratories at the 
Lineberger Comprehensive Cancer Center, University 
of North Carolina (courtesy of Drs. Bernard Weissman 
and Ian Davis). Control cell line Hh-Wt-fibroblasts were 
obtained from Coriell Institute (GM02153). Cell lines 
were cultured in the indicated media composition and 
maintained in a 37°C incubator with 5% CO2 and under a 
humidified atmosphere. DMEM, EMEM, IMDM, RPMI 
1640, L-Glutamine, Insulin-Transferrin-Selenium-G, Pen/
Strep (100 U/mL penicillin and 100 μg/mL streptomycin) 
were obtained from Thermo Fisher Scientific; McCoy’s 
5A Medium Modified was obtained from American Type 
Culture Collection; FBS was obtained from GE Healthcare 
Life Sciences. All cell lines were authenticated by short-
tandem repeat (STR, 10 loci) profiling and routinely 
tested for mycoplasma contamination using MycoAlert 
mycoplasma detection kit (Lonza).
Compounds 
The NIH Chemical Genomics Center (NCGC) 
Pharmaceutical Collection (NPC) contains 2,816 
compounds [21]. Of these, 50% are approved by the 
United States Food and Drug Administration (FDA). The 
remaining drugs are in use in other countries and/or have 
been tested in clinical trials against a range of diseases. 
The MIPE (Mechanism Interrogation Plate) collection 
contains 1,912 oncology-focused agents, many of which 
also have been approved for human use or are under 
clinical trials [18–20].  
qHTS cell viability assay
Cells were assayed in growth media at a density of 
500–1,000 cells/well. Five μL of cells were dispensed into 
1,536-well, white, solid-bottom, TC-treated plates (Greiner 
Bio One) using a Multidrop dispenser and incubated 
at 37°C, 5% CO2, under a humidified atmosphere for 
5 hours. Twenty three nL of compounds and controls 
(neutral control DMSO or positive control bortezomib 
at final concentration of 2.3 µM) were subsequently 
transferred by Kalypsys pintool. For primary screens, the 
MIPE collection was tested at 11-point dilutions (final 
concentration range from 0.78 nM to 46 µM) and the 
NPC collection at 8-point dilutions (final concentration 
range from 0.59 nM to 46 µM). Compounds tested in 
follow-up screens were assayed at 11-point dilutions 
(final concentration range from 0.78 nM to 46 µM).  Cells 
were incubated for 48 hours, followed by addition of 
3 µL of CellTiter-Glo (Promega), then after a ~15 minute 
incubation at RT, samples were analyzed for luminescence 
intensity using a ViewLux High-throughput CCD imager 
equipped with clear filters.
qHTS viability assay in 3D cultures
Cells were assayed in phenol red-free growth media 
at a density of 1,000 cells/well, with the exception of 
Daoy, and SH-N-SH which were assayed at 1,500 cells/
well. Thirty μL of cells were dispensed into 384-well, 
ULA, round bottom plates (Corning) using a Multidrop 
dispenser. Plates were spun down at 1,000 rpm for 1 
min and incubated at 37°C, 5% CO2, under a humidified 
atmosphere for either 24 (Daoy) or 48 hours (all other 
cell lines) to allow spheroid formation. Ninety two nL 
of compounds and controls (neutral control DMSO or 
positive control bortezomib at final concentrations of 
0.5 µM) were subsequently transferred via GNF Pintool. 
Plates were sealed using a breathable seal (Diversified 
Biotech, Dedham, MA) and incubated for 72 hours at 
37°C. Spheroid viability was first determined by high-
content imaging using Hoechst 33342 and Propidium 
Iodide (PI, ThermoFisher Scientific), followed by addition 
of CellTiter-Glo 3D (Promega). Specifically, 3 μL/well 
of PBS containing a 1:500 dilution of both dyes were 
dispensed using Multidrop. Dyes were incubated for 1 hour 
before imaging using the Celigo Image Cytometer. Then, 
20 μl of CellTiter-Glo 3D were added per well. Plates 
were incubated for 30 min at RT on a VWR microplate 
shaker (300 rpm) and analyzed for luminescence intensity 
using a ViewLux High-throughput CCD imager equipped 
with clear filters.
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Image analysis was done using the Celigo 
Tumorsphere 1+2+3 application software as previously 
described [45]. Briefly, spheroids were first identified 
using bright-field image segmentation, and then the 
fluorescent intensities of PI and Hoechst 3342 were 
obtained using red (EX: 531/40 nm, EM: 629/53 nm) 
and blue (EX: 377/50 nm, EM: 470/22 nm) filters, 
respectively. The data were exported to Excel, and the 
average fluorescent intensities were used to calculate 
the ratio of PI over Hoechst, which was used to quantify 
viability. Percent activity based on neutral and positive 
control bortezomib was derived and fitted as described in 
the qHTS data analysis and statistics section below. 
qHTS apoptosis assay in 3D cultures 
Apoptosis assays were carried out as above with the 
difference that compounds were incubated for 24 hours 
before addition of CellEvent Caspase-3/7 green detection 
reagent (TheremoFisher Scientific). Staurosporine at final 
concentrations of 3 µM was used as positive control. 
Spheroids were imaged using bright-field and green (EX: 
483/32 nM, EM: 536/40 nM) filters and analyzed with the 
Celigo Tumorsphere 1+2 application software. Spheroids 
were first identified using bright-field segmentation, and 
the average fluorescent intensity of the green channel was 
used to quantify caspase activation as percent activity 
based on neutral and positive controls (see qHTS data 
analysis and statistics below). 
qHTS data analysis and statistics 
The screening data was analyzed using software 
developed internally in NIH Chemical Genomics Center. 
Data from each assay were normalized plate-wise to 
corresponding intra-plate controls as described previously 
[46]. The same controls were also used for the calculation 
of the Z’ factor index for each assay.  The Z’ factor, a 
measure of assay quality control, was determined by Z′ 
= 1 – (3 × SDpositive + 3 × SDneutral)/(Meanpositive – Meanneutral) 
where SD is the standard deviation [47]. Supplementary 
Table 2 shows S:B and Z’ values for all primary and 
follow-up screens. Percent activity was derived using 
in-house software (http://tripod.nih.gov/curvefit/). Dose-
response curves were classified as described previously 
[22]. All concentration–response curves (CRC) were 
fitted, and IC50 were calculated with the GraphPad Prism
® 
software (GraphPad, San Diego, CA). Data sets were 
generated for each cell line against each of the drugs 
which included an activity score based on potency (IC50), 
maximum responses, curve classes, fit log IC50, and fit 
Hill slopes. Compounds exhibiting high-quality CRCs 
(class -1 and -2), and CellTiter-Glo signals six standard 
deviations below the population of neutral control wells, 
were considered active. Activity was further refined by 
imposing a cutoff IC50 of <10 µM, and Maximal response 
>65%. In the case of spheroid assays, each compound was 
tested in triplicate. Compounds were considered active 
when 2 or 3 replicates passed the above cutoffs.
Clustering of compounds by activity profiles
Compounds were clustered hierarchically within 
TIBCO Spotfire 6.0.0 based on their activity outcomes 
from the primary or follow-up screen across cell lines. 
Either compound’s potency or compound’s AUC (Area 
Under the Curve, calculated based on the qHTS data 
analysis and curve fittings), were utilized for clustering. 
In the heatmap, darker color indicates compounds that 
are more potent and efficacious, i.e. high-quality actives, 
and lighter color indicates for less potent and efficacious 
compounds. If a compound didn’t show any activity in 
an assay, it was highlighted as white in the heatmap. In 
potency-based heatmaps, inactive compounds that have no 
IC50 values determined were showed up as grey. 
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